Phio Pharmaceuticals Files 8-K

Ticker: PHIO · Form: 8-K · Filed: Apr 9, 2025 · CIK: 1533040

Phio Pharmaceuticals Corp. 8-K Filing Summary
FieldDetail
CompanyPhio Pharmaceuticals Corp. (PHIO)
Form Type8-K
Filed DateApr 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

Phio Pharma filed an 8-K on April 9, 2025, likely with financial updates and other key events.

AI Summary

On April 9, 2025, Phio Pharmaceuticals Corp. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business occurrences. No specific financial figures or new events were detailed in the provided excerpt.

Why It Matters

This filing signals that Phio Pharmaceuticals Corp. is making material disclosures to the SEC, which could impact investors' understanding of the company's current status and future prospects.

Risk Assessment

Risk Level: low — The filing is a standard disclosure document (8-K) and the provided excerpt does not contain specific negative or positive material information.

Key Players & Entities

  • Phio Pharmaceuticals Corp. (company) — Registrant
  • April 9, 2025 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • Marlborough, Massachusetts (location) — Principal executive offices
  • RXi Pharmaceuticals Corp (company) — Former company name

FAQ

What specific "Other Events" are being reported by Phio Pharmaceuticals Corp. on April 9, 2025?

The provided excerpt of the 8-K filing does not detail the specific "Other Events" being reported.

What is the significance of filing under "Financial Statements and Exhibits"?

This indicates that the company is providing updated financial information or submitting relevant exhibits, which could include financial reports or other supporting documents.

When was Phio Pharmaceuticals Corp. previously known as RXi Pharmaceuticals Corp?

The date of the name change from RXi Pharmaceuticals Corp. to Phio Pharmaceuticals Corp. was October 19, 2011.

What is the principal business address of Phio Pharmaceuticals Corp.?

The principal executive offices are located at 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, Massachusetts 01752.

What is the SIC code for Phio Pharmaceuticals Corp.?

The Standard Industrial Classification (SIC) code for Phio Pharmaceuticals Corp. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 9, 2025 regarding Phio Pharmaceuticals Corp. (PHIO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.